Health Economics›Venous thromboembolism›VTE primary prophylaxis

VTE primary prophylaxis

Venous thromboembolism · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Enoxaparin monotherapy Variant #01	—	R 54 916	14d	—	—	~1	~R 54 916 indirect	—
Apixaban monotherapy Variant #05	—	R 84	180d	—	—	~1	~R 84 indirect	—
Rivaroxaban monotherapy Variant #05	—	R 72	90d	—	—	~1	~R 72 indirect	—
Aspirin monotherapy Variant #01	—	R 26	28d	—	—	~2	~R 52 indirect	—
Observation Partial	—	—	—	~10.3 mo	~37.1 mo	—	—	65
Betrixaban monotherapy Variant #01 Partial	—	—	42d	—	—	~1	—	—
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145

7 of 7 regimens shown